Funding for this research was provided by:
Received: 8 March 2017
Accepted: 22 August 2017
First Online: 7 September 2017
Ethics approval and consent to participate
: This prospective study is Health Insurance Portability and Accountability Act (HIPAA) compliant and is approved by the Institutional Review Boards at the San Francisco VA Medical Center and University of California, San Francisco, the Johns Hopkins School of Medicine, and Yale University. For all research subjects, written informed consent to participate in the study will be obtained from participants before study interventions.
: Not applicable.
: CPCV, MGS, AT, CP, RDM, EV and MME have no relevant conflicts of interest to report. JMMT reports financial activities non-related to this article by QUARK Pharmaceutical. MGA reports financial activities non related to this article by QUARK Pharmaceutical and GILEAD Pharmaceutical.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.